Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
PCSA
Valuation N/A
Processa Pharmaceuticals, Inc.
Price$1.96
Model IV—
P/IV—
PCSC
Valuation N/A
Perceptive Capital Solutions Corp
Price$11.95
Model IV—
P/IV—
PCVX
Valuation N/A
Vaxcyte, Inc.
Price$59.54
Model IV—
P/IV—
PDEX
Deeply overvalued
PRO DEX INC
Price$62.81
Model IV$44.41
P/IV1.46
Premium +41%
Return to IV: -29.3%
Market implies -0.6%/yr
vs model +15.0% · below model
PDSB
Valuation N/A
PDS Biotechnology Corp
Price$0.29
Model IV—
P/IV—
PEN
Deeply overvalued
Penumbra Inc
Price$317.73
Model IV$221.14
P/IV1.44
Premium +44%
Return to IV: -30.4%
Market implies -4.4%/yr
vs model +17.1% · below model
PEPG
Valuation N/A
PepGen Inc.
Price$2.98
Model IV—
P/IV—
PFE
Fairly valued
PFIZER INC
Price$27.66
Model IV$30.77
P/IV0.85
Discount 10%
Return to IV: +11.2%
Owner yield 5.0%
10-yr IRR 5.8% · steady
Market implies +1.3%/yr
vs model +3.0% · in line
PFSA
Valuation N/A
Profusa, Inc.
Price$2.43
Model IV—
P/IV—
Market implies +33.5%/yr
vs model +15.0% · above model
PGEN
Valuation N/A
PRECIGEN, INC.
Price$6.85
Model IV—
P/IV—
Market implies +109.0%/yr
vs model +2.0% · above model
PGNY
Deeply undervalued
Progyny, Inc.
Price$27.76
Model IV$40.77
P/IV0.63
Discount 32%
Return to IV: +46.9%
Owner yield 7.4%
10-yr IRR 21.0% · grower
Market implies +13.2%/yr
vs model +24.4% · below model
PHAR
Undervalued
Pharming Group N.V.
Price$10.55
Model IV$13.22
P/IV0.85
Discount 20%
Return to IV: +25.3%
Market implies +7.7%/yr
vs model +15.1% · below model
PHAT
Deeply overvalued
Phathom Pharmaceuticals, Inc.
Price$8.68
Model IV$2.09
P/IV4.58
Premium +315%
Return to IV: -75.9%
Market implies +20.8%/yr
vs model +15.0% · above model
PHG
Valuation N/A
KONINKLIJKE PHILIPS NV
Price$24.59
Model IV—
P/IV—
PHGE
Valuation N/A
BiomX Inc.
Price$0.97
Model IV—
P/IV—
PHIO
Valuation N/A
Phio Pharmaceuticals Corp.
Price$1.03
Model IV—
P/IV—
PHVS
Valuation N/A
Pharvaris N.V.
Price$38.86
Model IV—
P/IV—
PIII
Valuation N/A
P3 Health Partners Inc.
Price$8.43
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +26.0% · below model
PIIIW
Valuation N/A
P3 Health Partners Inc.
Price$0.01
Model IV—
P/IV—
PLRX
Valuation N/A
PLIANT THERAPEUTICS, INC.
Price$1.12
Model IV—
P/IV—
Market implies +47.7%/yr
vs model +15.0% · above model
PLRZ
Valuation N/A
Polyrizon Ltd.
Price$11.03
Model IV—
P/IV—
PLSE
Valuation N/A
PULSE BIOSCIENCES, INC.
Price$53.11
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
PLSM
Valuation N/A
Pulsenmore Ltd.
Price$2.41
Model IV—
P/IV—
PLUR
Valuation N/A
Pluri Inc.
Price$1.18
Model IV—
P/IV—
Market implies +15.2%/yr
vs model +15.0% · in line
PLX
Valuation N/A
Protalix BioTherapeutics, Inc.
Price$2.64
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +8.3% · above model
PLYX
Valuation N/A
Polaryx Therapeutics, Inc.
Price$2.01
Model IV—
P/IV—
PMCB
Valuation N/A
PharmaCyte Biotech, Inc.
Price$0.45
Model IV—
P/IV—
PMI
Valuation N/A
Picard Medical, Inc.
Price$6.26
Model IV—
P/IV—
Market implies +25.2%/yr
vs model +12.5% · above model
PMN
Valuation N/A
ProMIS Neurosciences Inc.
Price$13.56
Model IV—
P/IV—
PMVP
Valuation N/A
PMV Pharmaceuticals, Inc.
Price$1.40
Model IV—
P/IV—
PNTG
Fairly valued
Pennant Group, Inc.
Price$39.20
Model IV$30.38
P/IV1.13
Premium +29%
Return to IV: -22.5%
Owner yield 2.2%
10-yr IRR 4.1% · grower
Market implies +15.9%/yr
vs model +17.8% · in line
POAS
Valuation N/A
PHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd
Price$0.17
Model IV—
P/IV—
Market implies +17.2%/yr
vs model +15.0% · in line
POCI
Deeply undervalued
PRECISION OPTICS CORPORATION, INC.
Price$4.36
Model IV$9.70
P/IV0.56
Discount 55%
Return to IV: +122.4%
Market implies -21.3%/yr
vs model +15.6% · below model
PODD
Deeply undervalued
INSULET CORP
Price$140.60
Model IV$249.75
P/IV0.58
Discount 44%
Return to IV: +77.6%
Owner yield 2.5%
10-yr IRR 5.5% · grower
Market implies +8.2%/yr
vs model +20.7% · below model
PPBT
Valuation N/A
PURPLE BIOTECH LTD.
Price$1.72
Model IV—
P/IV—
PPCB
Valuation N/A
Propanc Biopharma, Inc.
Price$0.92
Model IV—
P/IV—
PRAX
Valuation N/A
Praxis Precision Medicines, Inc.
Price$330.55
Model IV—
P/IV—
Market implies +87.0%/yr
vs model +15.0% · above model
PRCT
Deeply undervalued
PROCEPT BioRobotics Corp
Price$20.38
Model IV$40.36
P/IV0.65
Discount 50%
Return to IV: +98.0%
Market implies -12.4%/yr
vs model +50.0% · below model
PRE
Valuation N/A
Prenetics Global Ltd
Price$23.47
Model IV—
P/IV—
PRENW
Valuation N/A
Prenetics Global Ltd
Price$0.01
Model IV—
P/IV—
PRFX
Valuation N/A
PRF Technologies Ltd.
Price$0.86
Model IV—
P/IV—
Market implies +59.8%/yr
vs model +15.0% · above model
PRGO
Deeply overvalued
PERRIGO Co plc
Price$13.66
Model IV$8.04
P/IV1.37
Premium +70%
Return to IV: -41.1%
Owner yield 12.2%
10-yr IRR 19.9% · steady
Market implies +9.4%/yr
vs model +3.5% · above model
PRLD
Valuation N/A
Prelude Therapeutics Inc
Price$4.59
Model IV—
P/IV—
Market implies +64.0%/yr
vs model +15.0% · above model
PRME
Valuation N/A
Prime Medicine, Inc.
Price$3.13
Model IV—
P/IV—
Market implies +88.0%/yr
vs model +15.0% · above model
PROF
Valuation N/A
Profound Medical Corp.
Price$5.97
Model IV—
P/IV—
Market implies +37.5%/yr
vs model +15.0% · above model
PROK
Valuation N/A
PROKIDNEY CORP.
Price$1.80
Model IV—
P/IV—
PRPO
Deeply undervalued
Precipio, Inc.
Price$27.16
Model IV$99.09
P/IV0.23
Discount 73%
Return to IV: +264.8%
Market implies -31.4%/yr
vs model +29.2% · below model
PRQR
Valuation N/A
ProQR Therapeutics N.V.
Price$1.86
Model IV—
P/IV—
PRTA
Valuation N/A
PROTHENA CORP PUBLIC LTD CO
Price$8.93
Model IV—
P/IV—
Market implies +72.8%/yr
vs model +2.0% · above model
PRVA
Fairly valued
Privia Health Group, Inc.
Price$20.36
Model IV$17.71
P/IV1.21
Premium +15%
Return to IV: -13.0%
Owner yield 4.5%
10-yr IRR 13.4% · grower
Market implies +15.7%/yr
vs model +18.2% · in line
PSNL
Valuation N/A
Personalis, Inc.
Price$16.21
Model IV—
P/IV—
Market implies +95.8%/yr
vs model +2.0% · above model
PSTV
Valuation N/A
PLUS THERAPEUTICS, INC.
Price$3.84
Model IV—
P/IV—
Market implies +70.9%/yr
vs model +15.0% · above model
PTCT
Deeply undervalued
PTC THERAPEUTICS, INC.
Price$66.06
Model IV$345.26
P/IV0.21
Discount 81%
Return to IV: +422.6%
Market implies -4.3%/yr
vs model +25.0% · below model
PTGX
Valuation N/A
Protagonist Therapeutics, Inc
Price$148.18
Model IV—
P/IV—
Market implies +35.8%/yr
vs model +13.9% · above model
PTHS
Deeply overvalued
Pelthos Therapeutics Inc.
Price$21.90
Model IV$17.93
P/IV1.48
Premium +22%
Return to IV: -18.1%
Market implies -4.3%/yr
vs model +15.0% · below model
PTN
Valuation N/A
PALATIN TECHNOLOGIES INC
Price$10.94
Model IV—
P/IV—
Market implies -6.8%/yr
vs model +15.0% · below model
PULM
Valuation N/A
Pulmatrix, Inc.
Price$1.41
Model IV—
P/IV—
Market implies -11.2%/yr
vs model +15.0% · below model
PVLA
Valuation N/A
PALVELLA THERAPEUTICS, INC.
Price$150.13
Model IV—
P/IV—
Market implies +53.5%/yr
vs model +15.0% · above model
PYPD
Valuation N/A
PolyPid Ltd.
Price$5.33
Model IV—
P/IV—
PYXS
Valuation N/A
Pyxis Oncology, Inc.
Price$3.21
Model IV—
P/IV—
Market implies +38.4%/yr
vs model +15.0% · above model